Sionna Therapeutics downgraded at Freedom Broker with unchanged target

As previously reported, Freedom Broker analyst Ilya Zubkov downgraded Sionna Therapeutics (SION) to Hold from Buy with an unchanged price target of $38. Sionna’s Q1 update confirms that clinical execution is meeting all internal timelines for a pivotal summer 2026 catalyst window, though material results regarding patient efficacy have not yet been published, says the analyst. The firm’s likelihood of approval view remains unchanged until the upcoming readouts resolve the fundamental biological risk of the NBD1 stabilizer mechanism, the analyst added.